Zoledronic acid

Zoledronic acid (118072-93-8) is a potent inhibitor of bone resorption (IC50 = 2 nM in mouse calvarial cultures).1 The mechanism of its action is thought to be via inhibition of osteoclastic activity, induction of osteoclast apoptosis and blockage of osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid is a clinically useful drug for treatment of osteoporosis2, hypercalcemia of malignancy(HCM), multiple myeloma and bone metastases from solid tumors3. It has also been investigated as an antitumor agent and showing efficacy as an adjuvant therapy in several cancers.4,5 References/Citations: 1) Green et al. (1994), Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound; J. Bone Miner. Res., 9 7452) Deeks and Perry (2008) Zoledronic acid: a review of its use in the treatment of osteoporosis; Drugs Aging, 25 9633) Perry and Figgitt (2004), Zoledronic acid: a review of its use in patients with advanced ca